{"id":"https://openalex.org/W2155205362","doi":"https://doi.org/10.1158/1078-0432.ccr-12-1322","title":"CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs","display_name":"CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs","publication_year":2012,"publication_date":"2012-08-28","ids":{"openalex":"https://openalex.org/W2155205362","doi":"https://doi.org/10.1158/1078-0432.ccr-12-1322","mag":"2155205362","pmid":"https://pubmed.ncbi.nlm.nih.gov/22929806","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/3474704"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.ccr-12-1322","doi":"https://doi.org/10.1158/1078-0432.ccr-12-1322","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-12-1322","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"http://europepmc.org/articles/PMC3474704","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5107679458","display_name":"Mike I. Walton","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Mike I. Walton","raw_affiliation_strings":["Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112904632","display_name":"Paul D. Eve","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Paul D. Eve","raw_affiliation_strings":["Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061423488","display_name":"Angela Hayes","orcid":"https://orcid.org/0000-0001-6788-5761","observed_orcids":["https://orcid.org/0000-0001-6788-5761"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Angela Hayes","raw_affiliation_strings":["Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089603827","display_name":"Melanie R. Valenti","orcid":"https://orcid.org/0000-0001-7610-1375","observed_orcids":["https://orcid.org/0000-0001-7610-1375"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Melanie R. Valenti","raw_affiliation_strings":["Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072865677","display_name":"Alexis K. de Haven Brandon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Alexis K. De Haven Brandon","raw_affiliation_strings":["Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110967569","display_name":"Gary Box","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Gary Box","raw_affiliation_strings":["Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046795271","display_name":"Albert Hallsworth","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Albert Hallsworth","raw_affiliation_strings":["Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045911700","display_name":"Elizabeth L. Smith","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Elizabeth L. Smith","raw_affiliation_strings":["Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109601907","display_name":"Kathy J. Boxall","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Kathy J. Boxall","raw_affiliation_strings":["Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023760724","display_name":"Michael D. Lainchbury","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Michael Lainchbury","raw_affiliation_strings":["Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005028213","display_name":"Thomas P. Matthews","orcid":"https://orcid.org/0000-0002-4765-7734","observed_orcids":["https://orcid.org/0000-0002-4765-7734"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Thomas P. Matthews","raw_affiliation_strings":["Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090563561","display_name":"Yann Jamin","orcid":"https://orcid.org/0000-0003-0350-3757","observed_orcids":["https://orcid.org/0000-0003-0350-3757"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Yann Jamin","raw_affiliation_strings":["Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102963210","display_name":"Simon P. Robinson","orcid":"https://orcid.org/0000-0003-4101-7274","observed_orcids":["https://orcid.org/0000-0003-4101-7274"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Simon P. Robinson","raw_affiliation_strings":["Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019001132","display_name":"G. Wynne Aherne","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"G. Wynne Aherne","raw_affiliation_strings":["Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":null,"display_name":"John C. Reader","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"John C. Reader","raw_affiliation_strings":["Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064760601","display_name":"Louis Chesler","orcid":"https://orcid.org/0000-0001-7842-2068","observed_orcids":["https://orcid.org/0000-0001-7842-2068"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Louis Chesler","raw_affiliation_strings":["Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058014829","display_name":"Florence I. Raynaud","orcid":"https://orcid.org/0000-0003-0957-6279","observed_orcids":["https://orcid.org/0000-0003-0957-6279"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Florence I. Raynaud","raw_affiliation_strings":["Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110523635","display_name":"Suzanne A. Eccles","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Suzanne A. Eccles","raw_affiliation_strings":["Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007384881","display_name":"Ian Collins","orcid":"https://orcid.org/0000-0002-8143-8498","observed_orcids":["https://orcid.org/0000-0002-8143-8498","https://orcid.org/0000-0001-6936-0942"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Ian Collins","raw_affiliation_strings":["Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5015193618","display_name":"Michelle Dawn Garrett","orcid":"https://orcid.org/0000-0002-3939-1673","observed_orcids":["https://orcid.org/0000-0002-3939-1673"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Michelle D. Garrett","raw_affiliation_strings":["Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5107679458"],"corresponding_institution_ids":["https://openalex.org/I142947616"],"apc_list":null,"apc_paid":null,"fwci":4.1098,"has_fulltext":false,"cited_by_count":92,"citation_normalized_percentile":{"value":0.95482709,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"18","issue":"20","first_page":"5650","last_page":"5661"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10123","display_name":"DNA Repair Mechanisms","score":0.9053000211715698,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10123","display_name":"DNA Repair Mechanisms","score":0.9053000211715698,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.029600000008940697,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10583","display_name":"Cancer-related Molecular Pathways","score":0.02879999950528145,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chk1-inhibitor","display_name":"CHK1 inhibitor","score":0.9950000047683716},{"id":"https://openalex.org/keywords/cell-cycle-checkpoints","display_name":"cell cycle checkpoints","score":0.7699999809265137},{"id":"https://openalex.org/keywords/dna-damage-response","display_name":"DNA damage response","score":0.7630000114440918},{"id":"https://openalex.org/keywords/replication-fork-stability","display_name":"replication fork stability","score":0.753000020980835},{"id":"https://openalex.org/keywords/gemcitabine","display_name":"gemcitabine","score":0.8510000109672546},{"id":"https://openalex.org/keywords/irinotecan","display_name":"irinotecan","score":1.0},{"id":"https://openalex.org/keywords/oral-bioavailability","display_name":"oral bioavailability","score":0.7490000128746033},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.6439999938011169},{"id":"https://openalex.org/keywords/tumor-xenografts","display_name":"tumor xenografts","score":0.7990000247955322},{"id":"https://openalex.org/keywords/drug-combination-therapy","display_name":"drug combination therapy","score":0.3569999933242798}],"concepts":[{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5626477599143982},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4950951635837555},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.43201613426208496},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.20726892352104187}],"mesh":[{"descriptor_ui":"D000071877","descriptor_name":"Checkpoint Kinase 1","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000631","descriptor_name":"Aminopyridines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008822","descriptor_name":"Mice, Transgenic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009374","descriptor_name":"Neoplasms, Experimental","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009374","descriptor_name":"Neoplasms, Experimental","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D009447","descriptor_name":"Neuroblastoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009447","descriptor_name":"Neuroblastoma","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D011494","descriptor_name":"Protein Kinases","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D011494","descriptor_name":"Protein Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D014408","descriptor_name":"Biomarkers, Tumor","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D014408","descriptor_name":"Biomarkers, Tumor","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D015972","descriptor_name":"Gene Expression Regulation, Neoplastic","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D059447","descriptor_name":"Cell Cycle Checkpoints","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false}],"locations_count":5,"locations":[{"id":"doi:10.1158/1078-0432.ccr-12-1322","doi":"https://doi.org/10.1158/1078-0432.ccr-12-1322","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-12-1322","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},{"id":"pmid:22929806","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22929806","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical cancer research : an official journal of the American Association for Cancer Research","raw_type":"Journal Article"},{"id":"pmh:oai:europepmc.org:2620053","doi":null,"is_oa":true,"landing_page_url":"http://europepmc.org/articles/PMC3474704","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"","raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:3474704","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3474704","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Clin Cancer Res","raw_type":"Text"},{"id":"pmh:oai:kar.kent.ac.uk:58558","doi":null,"is_oa":false,"landing_page_url":"https://kar.kent.ac.uk/58558/","pdf_url":null,"source":{"id":"https://openalex.org/S4377196264","display_name":"Kent Academic Repository (University of Kent)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I20581793","host_organization_name":"University of Kent","host_organization_lineage":["https://openalex.org/I20581793"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Article"}],"best_oa_location":{"id":"pmh:oai:europepmc.org:2620053","doi":null,"is_oa":true,"landing_page_url":"http://europepmc.org/articles/PMC3474704","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"","raw_type":"Text"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G1517190324","display_name":null,"funder_award_id":"C1060/A10334","funder_id":"https://openalex.org/F4320319985","funder_display_name":"Cancer Research UK"},{"id":"https://openalex.org/G1830539922","display_name":null,"funder_award_id":"C309/A11566","funder_id":"https://openalex.org/F4320319985","funder_display_name":"Cancer Research UK"},{"id":"https://openalex.org/G2189351810","display_name":"Evaluation and Qualification of Non-Invasive MRI Biomarkers Associated with Platelet-Derived Growth Factor (PDGF) Signalling In Vivo.","funder_award_id":"091763/Z/10/Z","funder_id":"https://openalex.org/F4320311904","funder_display_name":"Wellcome Trust"},{"id":"https://openalex.org/G2688353016","display_name":null,"funder_award_id":"A10334","funder_id":"https://openalex.org/F4320319985","funder_display_name":"Cancer Research UK"},{"id":"https://openalex.org/G3601372966","display_name":null,"funder_award_id":"11566","funder_id":"https://openalex.org/F4320319985","funder_display_name":"Cancer Research UK"},{"id":"https://openalex.org/G513727605","display_name":null,"funder_award_id":"C309/A8274","funder_id":"https://openalex.org/F4320319985","funder_display_name":"Cancer Research UK"},{"id":"https://openalex.org/G6606160081","display_name":null,"funder_award_id":"A8274","funder_id":"https://openalex.org/F4320319985","funder_display_name":"Cancer Research UK"},{"id":"https://openalex.org/G8172221596","display_name":null,"funder_award_id":"A11566","funder_id":"https://openalex.org/F4320319985","funder_display_name":"Cancer Research UK"}],"funders":[{"id":"https://openalex.org/F4320311904","display_name":"Wellcome Trust","ror":"https://ror.org/029chgv08"},{"id":"https://openalex.org/F4320319985","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67"},{"id":"https://openalex.org/F4320319990","display_name":"National Institute for Health and Care Research","ror":"https://ror.org/0187kwz08"},{"id":"https://openalex.org/F4320334626","display_name":"Medical Research Council","ror":"https://ror.org/03x94j517"},{"id":"https://openalex.org/F4320334627","display_name":"Engineering and Physical Sciences Research Council","ror":"https://ror.org/0439y7842"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":47,"referenced_works":["https://openalex.org/W93208105","https://openalex.org/W1538419182","https://openalex.org/W1650797637","https://openalex.org/W1974788629","https://openalex.org/W1997331071","https://openalex.org/W2003691881","https://openalex.org/W2003884609","https://openalex.org/W2008055481","https://openalex.org/W2008933923","https://openalex.org/W2009655852","https://openalex.org/W2023942118","https://openalex.org/W2024231564","https://openalex.org/W2030646897","https://openalex.org/W2033038382","https://openalex.org/W2037356096","https://openalex.org/W2044033792","https://openalex.org/W2048451721","https://openalex.org/W2067614594","https://openalex.org/W2072763778","https://openalex.org/W2076324577","https://openalex.org/W2086255242","https://openalex.org/W2089190410","https://openalex.org/W2095986441","https://openalex.org/W2097803438","https://openalex.org/W2102815568","https://openalex.org/W2104357345","https://openalex.org/W2107643519","https://openalex.org/W2114105734","https://openalex.org/W2115785123","https://openalex.org/W2117692326","https://openalex.org/W2121371748","https://openalex.org/W2124358755","https://openalex.org/W2131592745","https://openalex.org/W2134647795","https://openalex.org/W2135946515","https://openalex.org/W2139291133","https://openalex.org/W2140990686","https://openalex.org/W2144455387","https://openalex.org/W2145339037","https://openalex.org/W2149795092","https://openalex.org/W2151180466","https://openalex.org/W2164193797","https://openalex.org/W2170787272","https://openalex.org/W2175111709","https://openalex.org/W2316086376","https://openalex.org/W2327485242","https://openalex.org/W6672188561"],"related_works":["https://openalex.org/W2036522505","https://openalex.org/W7220955397","https://openalex.org/W2604598757","https://openalex.org/W2050678136","https://openalex.org/W2488349910","https://openalex.org/W2078451439","https://openalex.org/W2565820221","https://openalex.org/W2066967559","https://openalex.org/W2139291133","https://openalex.org/W2887679346"],"abstract_inverted_index":{"PURPOSE:":[0],"Many":[1],"tumors":[2],"exhibit":[3],"defective":[4],"cell-cycle":[5,73,143],"checkpoint":[6],"control":[7],"and":[8,21,42,47,61,72,96,124,128,142,151,158,165,183,232],"increased":[9],"replicative":[10],"stress.":[11],"CHK1":[12,39,53,111,138,201,230],"is":[13],"critically":[14],"involved":[15],"in":[16,86,97,100,131,156,159,190,213],"the":[17,118,220],"DNA":[18,163],"damage":[19,164],"response":[20],"maintenance":[22],"of":[23,92,120,137,170,180,200,224],"replication":[24],"fork":[25],"stability.":[26],"We":[27],"have":[28],"therefore":[29],"discovered":[30],"a":[31,63,87,210,214,225],"novel":[32],"potent,":[33],"highly":[34,226],"selective,":[35,227],"orally":[36,228],"active":[37,229],"ATP-competitive":[38],"inhibitor,":[40],"CCT244747,":[41],"present":[43],"its":[44],"preclinical":[45],"pharmacology":[46],"therapeutic":[48],"activity.":[49],"EXPERIMENTAL":[50],"DESIGN:":[51],"Cellular":[52],"activity":[54,83,112,141,179,208],"was":[55,68,84],"assessed":[56],"using":[57,70],"an":[58],"ELISA":[59],"assay,":[60],"cytotoxicity":[62,119],"SRB":[64],"assay.":[65],"Biomarker":[66],"modulation":[67,198],"measured":[69],"immunoblotting,":[71],"effects":[74],"by":[75,94,104,149,153,188],"flow":[76],"cytometry":[77],"analysis.":[78],"Single-agent":[79],"oral":[80,175],"CCT244747":[81,108,154,171,189,203,218],"antitumor":[82,178,207],"evaluated":[85],"MYCN-driven":[88,215],"transgenic":[89],"mouse":[90],"model":[91],"neuroblastoma":[93],"MRI":[95],"genotoxic":[98,240],"combinations":[99],"human":[101,192],"tumor":[102,133,168,193],"xenografts":[103],"growth":[105],"delay.":[106],"RESULTS:":[107],"inhibited":[109,152],"cellular":[110],"(IC(50)":[113],"29-170":[114],"nmol/L),":[115],"significantly":[116,186],"enhanced":[117,162,187],"several":[121,191],"anticancer":[122,241],"drugs,":[123],"abrogated":[125],"drug-induced":[126],"S":[127],"G(2)":[129],"arrest":[130],"multiple":[132],"cell":[134],"lines.":[135],"Biomarkers":[136],"(pS296":[139],"CHK1)":[140],"inactivity":[144],"(pY15":[145],"CDK1)":[146],"were":[147,172,185],"induced":[148],"genotoxics":[150],"both":[155,181],"vitro":[157],"vivo,":[160],"producing":[161],"apoptosis.":[166],"Active":[167],"concentrations":[169],"obtained":[173],"following":[174],"administration.":[176],"The":[177],"gemcitabine":[182],"irinotecan":[184],"xenografts,":[194],"giving":[195],"concomitant":[196],"biomarker":[197],"indicative":[199],"inhibition.":[202],"also":[204],"showed":[205],"marked":[206],"as":[209],"single":[211],"agent":[212],"neuroblastoma.":[216],"CONCLUSION:":[217],"represents":[219],"first":[221],"structural":[222],"disclosure":[223],"inhibitor":[231],"warrants":[233],"further":[234],"evaluation":[235],"alone":[236],"or":[237],"combined":[238],"with":[239],"therapies.":[242]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":9},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":9},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":6},{"year":2017,"cited_by_count":6},{"year":2016,"cited_by_count":9},{"year":2015,"cited_by_count":13},{"year":2014,"cited_by_count":9},{"year":2013,"cited_by_count":8},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}